Dyspeptic syndrome associated with antidiabetic therapy;Dyspeptický syndrom při antidiabetické léčbě

Vnitrni Lekarstvi

Volumn 57, Issue 4, 2011, Pages 391-395

  Šmahelová, Alena ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Acarbose; Incretin treatment; Lower dyspeptic syndrome; Metformin; Orlistat; Pancreatitis; Pneumatosis cystoides intestinalis; Upper dyspeptic syndrome

Indexed keywords

ACARBOSE; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; METFORMIN; SUCROSE; TETRAHYDROLIPSTATIN; LACTONE;

ABDOMINAL PAIN; ACUTE PANCREATITIS; APPETITE DISORDER; ARTICLE; DIARRHEA; DYSPEPSIA; FAT INTAKE; HUMAN; NAUSEA; PNEUMATOSIS INTESTINALIS; TASTE DISORDER; VOMITING; CHEMICALLY INDUCED DISORDER; REVIEW;

ACARBOSE; DYSPEPSIA; HUMANS; HYPOGLYCEMIC AGENTS; LACTONES; METFORMIN;

EID: 79955934897     PISSN: 0042773X     EISSN: 18017592     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Schernthaner G, Barnett AH, Betteridge DJ et al. Is the ADA/EASD algorithm for the management of type 2 diabetes (January 2009) based on evidence or opinion? A critical analysis. Diabetologia 2010; 53: 1258-1269.
2. Nathan DM, Davidson MB, DeFronzo RA et al. American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753-759. (Pubitemid 46354366)
3. Svačina Š. Postavení metforminu jako antidiabetika první olby. Vnitř Lék 2010; 56: 1225-1227.
4. eMC. SPC Glucobay 50mg tablets. http://www.medicines.org.uk/emc/medicine/ 19972/SPC/Glucobay+50m-g+tablets/.
5. Vogel Y, Buchner NJ, Szpakowski M et al. Pneumatosis cystoides intestinalis of the ascending colon related to acarbose treatment: a case report. J Med Case Reports 2009; 3: 9216.
6. Tsujimoto T, Shioyama E, Moriya K. Pneumatosis cystoides intestinalis following alpha-glucosidase inhibitor treatment: a case report and review of the literature. World J Gastroenterol 2008; 14: 6087-6092.
7. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-161. (Pubitemid 38196725)
8. Chanoine JP, Hampl S, Jensen C et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA 2005; 293: 2873-2883. (Pubitemid 41029141)
9. Šmahelová A. Nová farmaka v léč bě diabetu a s čím se může dnes praktický lékař setkat. In: Léčba diabetika v praxi V. Praha: JS Partner, s.r.o. 2009.
10. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20: 876-913.
11. Flint A, Raben A, Astrup A et al. Gucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101: 515-520. (Pubitemid 28084232)
12. Wettergren A, Schjoldager B, Mortensen PE et al. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 1993; 38: 665-673.
13. During MJ, Cao L, Zuzga DS et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9: 1173-1179. (Pubitemid 37173702)
14. Klonoff DC, Buse JB, Nielsen LL et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008; 24: 275-286. (Pubitemid 351160260)
15. Gallwitz B. Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data. Int J Clin Pract 2006; 60: 1654-1661. (Pubitemid 44742167)
16. Barnett AH, Burger J, Johns D et al. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333-2348. (Pubitemid 350298125)
17. Buse JB, Rosenstock J, Sesti G et al. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
18. Garber A, Henry R, Ratner R et al. LEAD-3 (Mono) Study Group. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
19. Christensen M, Knop FK, Holst JJ et al. Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs 2009; 12: 503-513.
20. Vilsbøll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610 (Pubitemid 46871185)
21. SPC Galvus 50 mg tablets. http://www.ema.europa.eu/docs/en-GB/document- library/EPAR---Product-Information/human/000771/WC500020327.pdf.
22. Butler PC, Matveyenko AV, Dry S et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010; 53: 1-6.
23. Noel RA, Braun DK, Patterson RE et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009; 32: 834-838.
24. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009; 25: 1019-1027.
25. Anderson SL, Trujillo JM. Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010; 44: 904-909.
26. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafety- InformationforHeathcareProfessionals/ucm183764.htm
27. Engel SS, Williams-Herman DE, Golm GT et al. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010; 64: 984-990.
28. Stoffers DA, Kieffer TJ, Hussain MA et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741-748. (Pubitemid 30339989)
29. Landi S. Genetic predisposition and environmental risk factors to pancreatic cancer: A review of the literature. Mutat Res 2009; 681: 299-307.
30. Jura N, Archer H, Bar-Sagi D. Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res 2005; 15: 72-77. (Pubitemid 41653970)
31. Butler PC, Matveyenko AV, Dry S et al. Glucagon-like peptide-1 therapy and the exocrine pancreas: innocent bystander or friendly fire? Diabetologia 2010; 53: 1-6.
32. Matveyenko AV, Dry S, Cox HI et al. Beneficial endocrine but adverse exocrine effect of Sitagliptin in the human islet amyloid polypeptide transgenic rat model of type 2 diabetes, interactions with metformin. Diabetes 2009; 58: 1644-1645.